1-2 of 2
Larry Karnitz, PhD
Close
Sort by
Journal Articles

A Phase 1 Study of the PARP Inhibitor Veliparib in Combination with Temozolomide in Acute Leukemias

Ivana Gojo, MD, Jan H. Beumer, PharmD, PhD, Keith Pratz, MD, Jiuping Ji, Lihua Wang, PhD, Michelle A. Rudek, PharmD, PhD, Michael A. McDevitt, MD PhD, Maria R. Baer, MD, Amanda Blackford, ScM, B. Douglas Smith, MD, Steven D. Gore, MD, Hetty E. Carraway, MD MBA, Margaret M. Showel, MD, Mark J. Levis, MD PhD, Amy E. DeZern, MD MHS, Douglas Gladstone, MD, Tania Jain, MD, Jackie Greer, RN, Marie Pouquet, PharmD, Ali-walbi Ismail, PharmD, MS, James Herman, MD, Weijie Poh, PhD, Larry Karnitz, PhD, Scott H. Kaufmann, MD PhD, Alice Chen, MD, Judith E Karp, MD
Journal: Blood
Blood (2015) 126 (23): 1361.
https://doi.org/10.1182/blood.V126.23.1361.1361
Published: 2015
Journal Articles

Randomized Phase II Trial of Timed Sequential Cytosine Arabinoside with and without the CHK1 Inhibitor MK-8876 in Adults with Relapsed and Refractory Acute Myelogenous Leukemia

Jonathan Allen Webster, MD, Raoul Tibes, MD PhD, Amanda Blackford, ScM, Lawrence Morris, MD, Mrinal M Patnaik, MBBS, Lihua Wang, PhD, Melanie Rebechi, BS, Jacqueline Greer, RN, Mark R Litzow, MD, Larry Karnitz, PhD, Gary L. Rosner, Austin Doyle, MD, Scott H. Kaufmann, MD PhD, Judith E Karp, MD, B. Douglas Smith, MD
Journal: Blood
Blood (2015) 126 (23): 2563.
https://doi.org/10.1182/blood.V126.23.2563.2563
Published: 2015